Drug Discovery AI Talk

Same target, different weapon: why the delivery mechanism changes who a drug helps, and what AI design can predict about which modality fits which target. Produced by Dr. Jake Chen.

AI agents that read papers, run code, and steer experiments are moving from tools toward collaborators. This episode asks who really decides the next research step — the model, a fixed script, or the scientist — and what evidence would prove an agent actually plans rather than merely follows a script. It walks through an autonomy ladder, two landmark agent systems, and a practical pilot framework...

Three fresh stories, one question: what happens when AI stops being a chatbot and starts doing the work of a lab? A swarm of AI agents reads millions of brain cells in minutes and surfaces a new hypothesis for neurodegeneration. A robotics startup bets that machines can learn a chemist's hands. And a pharma giant gives its scientists an AI research partner. We walk through what each story actu...

Three fresh stories, one question: what happens when AI stops needing a protein's 3D shape and starts working with biology as it actually behaves? A virtual cell trained on proteins rather than genes predicts how cancer cells respond to drugs hour by hour. A new structure-free model finds drug binding sites on disordered proteins that no structure-based method can touch. And the first drug wit...

AI can now generate millions of molecules, thousands of drug targets, and entire scientific manuscripts in hours — but our capacity to validate any of it hasn't kept pace. This episode walks through the trust crisis in AI drug discovery: from ultra-large virtual screening libraries to AI-generated papers arriving faster than peer review can handle, from citation errors in machine-written manus...

Biohub's Virtual Biology Initiative just expanded to $1.8 billion — backed by the DOE, NIH, Google DeepMind, Isomorphic Labs, and Meta — to build the data foundations for predictive AI in biology. But a new perspective argues the field is celebrating too early: today's biological data are sparse across the spatial, temporal, and causal dimensions that actually determine how cells respond t...

On September 10, 2026, Insilico Medicine dosed the first patient in the Phase III GENESIS-IPF-3 trial of rentosertib (ISM001-055) for idiopathic pulmonary fibrosis - the first drug with both an AI-discovered target and an AI-designed molecule to reach Phase III. We break down the TNIK story, the Phase IIa data published in Nature Medicine, the provocative aging-clock signals in Nature Biotechnolog...

In this episode, we examine how AI-native biotechnology companies are reshaping drug discovery through the lens of their intellectual-property portfolios. The evidence suggests that these firms are becoming significantly more productive at generating patentable molecules, yet they have not demonstrated the same advantage in discovering entirely new biological targets. Companies such as Insilico Me...

In this podcast, we study how integrating agentic AI into autonomous wet labs promises rapid therapeutic innovation, while connecting autonomous models directly to physical lab instruments creates critical security risks. These range from immediate hazards—such as cyber-physical vulnerabilities, sequence-screening evasion, and flawed objective optimization—to systemic risks from unaligned superint...

For decades, KRAS stood as oncology’s archetypal “undruggable” target—a powerful cancer driver with no obvious pocket for conventional medicines to grasp. This episode explores how molecular-glue drugs such as daraxonrasib overturn that assumption by recruiting cyclophilin A to form a synthetic complex around active RAS, physically blocking its growth signals. From the structural ingenuity behind...

In this podcast, we show a pivotal shift in 2026 for AI drug discovery toward integrated, AI-native R&D systems that move beyond simple algorithmic tasks to form closed-loop learning environments. In this new phase, the industry focuses on converting physical experiments into causal data to overcome information bottlenecks that mere model scaling cannot solve. Leading experts emphasize that ge...

In this episode, we critically examine whether AI drug discovery is solving the hardest problems in medicine—or simply making the easier ones faster. At the center of the discussion is Daphne Koller’s argument that the industry has invested heavily in computational molecular design while giving too little attention to the deeper challenge of understanding human disease biology. If the primary bott...

In this episode, we venture beyond protein structure prediction into the messy, stochastic reality of modeling the virtual cell. We examine why biology still lacks an AlphaFold-like solution for predicting the behavior of entire cells and explore challenges spanning molecular interactions, cell-state transitions, perturbation responses, and clinical translation. Because cellular behavior is dynami...

What if we could turn a spark of biological insight into a real-world, life-saving treatment? That is the core mission of CollaboFest, an innovative initiative designed to break down the slow, traditional bottlenecks of drug discovery. Organized by the University of Alabama at Birmingham's Systems Pharmacology AI Research Center (SPARC), alongside Southern Research, this unique program unites mult...

In this episode, we explore the rapid evolution of molecular glues, a breakthrough in targeted protein degradation that stabilizes protein interactions to treat previously incurable diseases. Historically discovered by chance, this field is moving toward a systematic design approach by integrating artificial intelligence, functional genomics, and biased chemical libraries. Current research emphasi...

In this episode, we examine whether  increasing the size and depth of neural networks  truly enhances  molecular property prediction  compared to traditional machine learning. A recent study reveals that  classical models  using chemical fingerprints often outperform or match  deep learning architectures , particularly when dealing with limited datasets or local structural variations. While  found...

In this episode, we explore the evolving role of  Quantitative Systems Pharmacology (QSP)  in drug development, particularly as a mechanistic alternative to traditional animal testing. It details how mathematical modeling can integrate  human-relevant data  and  biological pathways  to better predict drug safety and efficacy before clinical trials. The sources highlight recent  2026 FDA draft guid...

In this episode, we explore Lilly TuneLab as a major signal of where AI drug discovery may be heading: toward powerful platform ecosystems that combine proprietary pharmaceutical data, advanced predictive models, federated learning, and large-scale compute. On the positive side, platforms like TuneLab could help biotech companies derisk drug assets earlier, improve safety and pharmacokinetic predi...

In this episode, we explore the surge of foundation models (FMs) within pharmaceutical research, noting that over 200 such models were published by early 2025. Unlike traditional task-specific AI, these versatile algorithms are pre-trained on massive datasets to identify broad biological patterns before being refined for specialized functions. We detail how FMs are currently applied to transcripto...

This podcast explores the transformative shift toward New Approach Methodologies (NAMs), which utilize human-relevant experimental and computational systems to modernize drug discovery and biomedical research. Major federal initiatives from the NIH and FDA are establishing a robust infrastructure for these technologies, moving them from peripheral alternatives to central organizing principles in r...

In this episode, we investigate the significant evolution of AI-driven toxicity prediction, detailing how the field has shifted from simple statistical models to sophisticated deep learning and multimodal systems. It highlights a variety of computational tools, distinguishing between modern machine learning platforms like ProTox 3.0 and established regulatory-facing frameworks such as the OECD QSA...

 In this episode, Dr. Jake Chen provides his narrative review and advocates for a fundamental shift in pharmaceutical research, moving away from inefficient trial-and-error toward an AI-augmented scientific discipline. The text outlines 12 core principles to transform drug discovery into a mechanism-aware system that prioritizes causal target biology, early safety prediction, and patient-centered...

Welcome to today's episode, where we dive into a monumental breakthrough in oncology, i.e., cracking the "undruggable" KRAS mutation. For decades, pancreatic cancer has been notoriously lethal, with few treatment options. Enter daraxonrasib (RMC-6236), a revolutionary "molecular glue" that targets the active "ON" state of mutated RAS proteins. In the recent Phase 3 RASolute 302 trial, this targete...

AI isn't replacing scientists in the lab — it's joining the team. This episode unpacks "capability complementarity," the framework where human creativity and contextual judgment fuse with AI's speed and scale to crack problems neither could solve alone. We explore multi-agent systems delegating molecule design, literature review, and analysis; why the "black-box" problem makes human-in-the-loop ov...

In this episode, we explore the  evolution of leadership  within the field of  AI-driven drug discovery , identifying key figures who are reshaping how medicines are developed. It categorizes these "mavericks" into  distinct archetypes , ranging from  industrialized data factory builders  like Chris Gibson to  biological systems reformers  like Aviv Regev. The analysis highlights that while  gener...